AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23817989 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-generation antipsychotic medications
Number of subjects: 108
Study 23817989 — intervention group
Group type: COMPARATOR
Intervention: Conventional antipsychotic medications
Number of subjects: 108
Study 23451547 — intervention group
Group type: EXPERIMENTAL
Intervention: Single take home dose of infant nevirapine
Number of subjects: 0
Study 23451547 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (no changes made)
Number of subjects: 0
Study 19142390 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic Touch - Krieger-Kunz Method
Number of subjects: 42
Study 19142390 — intervention group
Group type: COMPARATOR
Intervention: Mock technique (control)
Number of subjects: 42
Study 16368848 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring group: tracheal intubation at maximum block based on monitoring after atracurium 0.5 mg/kg
Number of subjects: 60
Study 16368848 — intervention group
Group type: COMPARATOR
Intervention: 2‐min group: tracheal intubation 2 min after injection of atracurium 0.5 mg/kg
Number of subjects: 60
Study 16368848 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring group
Number of subjects: 60
Study 16368848 — intervention group
Group type: COMPARATOR
Intervention: 2‐min group
Number of subjects: 60
Study 12839406 — intervention group
Group type: EXPERIMENTAL
Intervention: ID type III (n = 39)
Number of subjects: 118
Study 12839406 — intervention group
Group type: EXPERIMENTAL
Intervention: DJD group (n = 18)
Number of subjects: 118
Study 12839406 — intervention group
Group type: EXPERIMENTAL
Intervention: ID type I (n = 35)
Number of subjects: 118
Study 12839406 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 46)
Number of subjects: 118
Study 10376236 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonazepam (1-4 mg/d, flexible dose)
Number of subjects: 27
Study 10376236 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 9032843 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma Knife radiosurgery
Number of subjects: 0
Study 1794360 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole 50 mg/day
Number of subjects: 65
Study 1794360 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole 100 mg/day
Number of subjects: 65
Study 1794360 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 65
Study 6228936 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroergotoxin
Number of subjects: 100
Study 6228936 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 31777547 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium valproate (SV) + Levetiracetam (LEV)
Number of subjects: 120
Study 31777547 — intervention group
Group type: COMPARATOR
Intervention: Sodium valproate (SV)
Number of subjects: 120
Study 29744754 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed dye laser treatment for seven sessions at 2-week intervals
Number of subjects: 20
Study 29744754 — intervention group
Group type: COMPARATOR
Intervention: Pulsed dye laser treatment for three sessions at 6-week intervals
Number of subjects: 20
Study 27473749 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined magneto-auriculotherapy (MAT) plus laser auriculotherapy (LAT)
Number of subjects: 43
Study 27473749 — intervention group
Group type: EXPERIMENTAL
Intervention: Magneto-auriculotherapy (MAT)
Number of subjects: 43
Study 27473749 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser auriculotherapy (LAT)
Number of subjects: 43
Study 27473749 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 43
Study 25321188 — intervention group
Group type: EXPERIMENTAL
Intervention: buprenorphine/naloxone treatment for 4 weeks followed by dose tapering over 7 days
Number of subjects: 501
Study 25321188 — intervention group
Group type: EXPERIMENTAL
Intervention: buprenorphine/naloxone treatment for 4 weeks followed by dose tapering over 28 days
Number of subjects: 501
Study 22978414 — intervention group
Group type: EXPERIMENTAL
Intervention: PNPLA3 I148M allele in HCV genotype 2 infected patients
Number of subjects: 382
Study 22978414 — intervention group
Group type: COMPARATOR
Intervention: PNPLA3 I148M allele in HCV genotype 3 infected patients
Number of subjects: 382
Study 20520636 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of IgH translocations (especially t(14;16))
Number of subjects: 314
Study 20520636 — intervention group
Group type: EXPERIMENTAL
Intervention: FLC estimates
Number of subjects: 314
Study 20520636 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of abnormal FLC estimate and/or presence of high-risk IgH translocation
Number of subjects: 314
Study 18442352 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion SR
Number of subjects: 0
Study 18442352 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18442352 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger ST users and those with a history of depression
Number of subjects: 0
Study 15990911 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone social support and education for 13 months
Number of subjects: 197
Study 15990911 — intervention group
Group type: COMPARATOR
Intervention: Mailed educational resource kit
Number of subjects: 197
Study 11600561 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (800 microg/d for 2 months, then 400 microg/d)
Number of subjects: 60
Study 11600561 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (500 microg/d for 2 months, then 200 microg/d)
Number of subjects: 60
Study 11600561 — intervention group
Group type: COMPARATOR
Intervention: Cromone treatment (control group)
Number of subjects: 60
Study 9875641 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-HCV positive patients
Number of subjects: 1148
Study 9875641 — intervention group
Group type: COMPARATOR
Intervention: Non-cirrhotic patients
Number of subjects: 1148
Study 9875641 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 1148
Study 9875641 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-HCV positivity
Number of subjects: 1148
Study 9875641 — intervention group
Group type: EXPERIMENTAL
Intervention: HBsAg positivity
Number of subjects: 1148
Study 7991907 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic epidural block with bupivacaine (8 ml of 0.5% bupivacaine with adrenalin 1:200.000) administered 30 min before surgery and combined anesthesia with isoflurane.
Number of subjects: 30
Study 7991907 — intervention group
Group type: COMPARATOR
Intervention: Conventional balanced anesthesia with isoflurane and endovenous fentanyl (2.5 micrograms/kg) and saline solution administered through an epidural catheter.
Number of subjects: 30
Study 2575367 — intervention group
Group type: EXPERIMENTAL
Intervention: Cicletanine (50 to 100 mg/day) combined with beta-blockers
Number of subjects: 1668
Study 2575367 — intervention group
Group type: EXPERIMENTAL
Intervention: Cicletanine (50 to 100 mg/day) combined with calcium inhibitors
Number of subjects: 1668
Study 2575367 — intervention group
Group type: EXPERIMENTAL
Intervention: Cicletanine (50 to 100 mg/day) combined with angiotensin-converting enzyme inhibitors
Number of subjects: 1668
Study 2575367 — intervention group
Group type: EXPERIMENTAL
Intervention: Cicletanine (50 to 100 mg/day)
Number of subjects: 1668
Study 182348 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogens (Premarin, Provera, diethylstilbestrol)
Number of subjects: 0
Study 182348 — intervention group
Group type: COMPARATOR
Intervention: Placebo or Provera
Number of subjects: 0
Study 182348 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments combined (Stage III and IV patients)
Number of subjects: 0
Study 182348 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated pretreatment fibrinogen levels
Number of subjects: 0
Study 31377692 — intervention group
Group type: EXPERIMENTAL
Intervention: REACH‐HF intervention (self‐help manual for patients with HFrEF and caregivers facilitated over 12 weeks by trained healthcare professionals)
Number of subjects: 160
Study 31377692 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative data from intervention participants and caregivers
Number of subjects: 160
Study 30550135 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratympanic injection of dexamethasone 0.5 ml
Number of subjects: 48
Study 30550135 — intervention group
Group type: COMPARATOR
Intervention: Postauricular injection of methylprednisolone 40 mg
Number of subjects: 48
Study 26499352 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics group A (1 g Clostridium butyricum MIYAIRI twice daily)
Number of subjects: 60
Study 26499352 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics group B (Bifidobacterium longum BB536 twice daily)
Number of subjects: 60
Study 26499352 — intervention group
Group type: EXPERIMENTAL
Intervention: Digestive enzymes group (Aczym, containing 100 mg takadiastase N, 20 mg cellulase AP, 50 mg lipase MY, and 100 mg pancreatin, twice daily)
Number of subjects: 60
Study 24837889 — intervention group
Group type: EXPERIMENTAL
Intervention: OAMCGT plus IMRT (arm 1; n=21)
Number of subjects: 44
Study 24837889 — intervention group
Group type: COMPARATOR
Intervention: IMRT only (arm 2; n=23)
Number of subjects: 44
Study 24837889 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 44
Study 21878847 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical dorzolamide 2%-timolol 0.5% twice a day
Number of subjects: 17
Study 21878847 — intervention group
Group type: COMPARATOR
Intervention: No additional drops (control group)
Number of subjects: 17
Study 19911481 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer support
Number of subjects: 224
Study 19911481 — intervention group
Group type: EXPERIMENTAL
Intervention: Pager messaging
Number of subjects: 224
Study 19911481 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 224
Study 17343821 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-treatment SSRI use
Number of subjects: 105
Study 17343821 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-treatment SSRI use
Number of subjects: 105
Study 17343821 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-treatment A/D use
Number of subjects: 105
Study 17343821 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-treatment A/D use
Number of subjects: 105
Study 17343821 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-treatment BZ use
Number of subjects: 105
Study 15295743 — intervention group
Group type: COMPARATOR
Intervention: Home-based resistance exercise program, 3 days per week for 12 weeks
Number of subjects: 20
Study 11211069 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear slides
Number of subjects: 0
Study 11211069 — intervention group
Group type: EXPERIMENTAL
Intervention: Disgust slides
Number of subjects: 0
Study 11211069 — intervention group
Group type: EXPERIMENTAL
Intervention: Erotic slides
Number of subjects: 0
Study 11211069 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurturant slides
Number of subjects: 0
Study 11211069 — intervention group
Group type: COMPARATOR
Intervention: Neutral slides
Number of subjects: 0
Study 9334143 — intervention group
Group type: EXPERIMENTAL
Intervention: Pefloxacin mesylate, administered twice a day in a daily dose of 0.8 to 1.2 g
Number of subjects: 0
Study 8440104 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal continuous positive airway pressure at 10 cm H2O
Number of subjects: 10
Study 8440104 — intervention group
Group type: COMPARATOR
Intervention: Mask continuous positive airway pressure at 10 cm H2O
Number of subjects: 10
Study 3440039 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (Pidilat)
Number of subjects: 12
Study 3440039 — intervention group
Group type: COMPARATOR
Intervention: Commercially available reference preparation
Number of subjects: 12
Study 31524967 — intervention group
Group type: EXPERIMENTAL
Intervention: Microneedling followed by topical application of 5-fluorouracil
Number of subjects: 27
Study 31524967 — intervention group
Group type: COMPARATOR
Intervention: Microneedling alone
Number of subjects: 27
Study 29638190 — intervention group
Group type: EXPERIMENTAL
Intervention: 11+ injury prevention programme
Number of subjects: 82
Study 29638190 — intervention group
Group type: COMPARATOR
Intervention: Standard warm-up (Control)
Number of subjects: 82
Study 26786148 — intervention group
Group type: EXPERIMENTAL
Intervention: P1000/Ca0 (1 g/d phosphorus)
Number of subjects: 62
Study 26786148 — intervention group
Group type: EXPERIMENTAL
Intervention: P1000/Ca500 (1 g/d phosphorus and 0.5 g/d calcium)
Number of subjects: 62
Study 26786148 — intervention group
Group type: EXPERIMENTAL
Intervention: P1000/Ca1000 (1 g/d phosphorus and 1 g/d calcium)
Number of subjects: 62
Study 26786148 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sherbet powder)
Number of subjects: 62
Study 26786148 — intervention group
Group type: EXPERIMENTAL
Intervention: All interventions
Number of subjects: 62
Study 24645901 — intervention group
Group type: EXPERIMENTAL
Intervention: Korean Parent Training Program (KPTP)
Number of subjects: 48
Study 23768674 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive training
Number of subjects: 135
Study 23768674 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative training
Number of subjects: 135
Study 23768674 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 135
Study 20610444 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 1043
Study 18825581 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support group attendance
Number of subjects: 440
Study 17373141 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine patch
Number of subjects: 0
Study 17373141 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid analgesics
Number of subjects: 0
Study 17373141 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 0
Study 17373141 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 0
Study 17373141 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 0
Study 17373141 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiviral and analgesic therapies
Number of subjects: 0
Study 17373141 — intervention group
Group type: EXPERIMENTAL
Intervention: Childhood vaccine against varicella zoster virus
Number of subjects: 0
Study 17373141 — intervention group
Group type: EXPERIMENTAL
Intervention: More potent vaccine against varicella for adults
Number of subjects: 0
Study 14649578 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin sealant (FS) 10 mL total
Number of subjects: 81
Study 14649578 — intervention group
Group type: COMPARATOR
Intervention: Standard of care alone
Number of subjects: 81
Study 11001889 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic methylprednisolone (0.5 mg/kg on days 14 to 20, 1 mg/kg on days 21 to 34, 0.5 mg/kg on days 35 to 48, tapered and discontinued on day 110)
Number of subjects: 108
Study 11001889 — intervention group
Group type: COMPARATOR
Intervention: No prophylactic methylprednisolone
Number of subjects: 108
Study 11001889 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic methylprednisolone
Number of subjects: 108
Study 9006240 — intervention group
Group type: EXPERIMENTAL
Intervention: diet and exercise program
Number of subjects: 118
Study 7970340 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with visible abdominal bloating
Number of subjects: 46
Study 7970340 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with visible abdominal bloating during episodes of bloating
Number of subjects: 46
Study 7970340 — intervention group
Group type: COMPARATOR
Intervention: Normal volunteers (control group)
Number of subjects: 46
Study 3307283 — intervention group
Group type: EXPERIMENTAL
Intervention: Immobilization for 3 weeks
Number of subjects: 112
Study 3307283 — intervention group
Group type: COMPARATOR
Intervention: Analgetic treatment without immobilization
Number of subjects: 112
Study 28987524 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted hand hygiene program (increased availability of alcohol-based handrub, HH promotion, staff education, local work groups)
Number of subjects: 26
Study 28987524 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 26
Study 26156412 — intervention group
Group type: EXPERIMENTAL
Intervention: CoQ10 supplementation (100 mg once a day for 12 weeks)
Number of subjects: 41
Study 26156412 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 25145970 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messages containing antenatal health information delivered in English, Xhosa, or Afrikaans according to participant preference
Number of subjects: 206
Study 25145970 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving no text messages
Number of subjects: 206
Study 21779958 — intervention group
Group type: EXPERIMENTAL
Intervention: Idebenone at a weight-adjusted dose of 1,350/2,250 mg/day for 12 months
Number of subjects: 68
Study 21779958 — intervention group
Group type: COMPARATOR
Intervention: Idebenone at a weight-adjusted dose of 450/900 or 1,350/2,250 mg/day for 6 months (during the IONIA study)
Number of subjects: 68
Study 21779958 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 months (during the IONIA study)
Number of subjects: 68
Study 21779958 — intervention group
Group type: EXPERIMENTAL
Intervention: Idebenone at a weight-adjusted dose of 1,350/2,250 mg/day for 12 months (IONIA-E study)
Number of subjects: 68
Study 19176289 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon‐beta (IFNbeta) treatment
Number of subjects: 219
Study 19176289 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 219
Study 19176289 — intervention group
Group type: COMPARATOR
Intervention: Untreated MS patients
Number of subjects: 219
Study 17445100 — intervention group
Group type: EXPERIMENTAL
Intervention: Eletriptan 40 mg
Number of subjects: 267
Study 17445100 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 267
Study 15621990 — intervention group
Group type: EXPERIMENTAL
Intervention: Training program for sentinel lymph node biopsy
Number of subjects: 226
Study 12475391 — intervention group
Group type: EXPERIMENTAL
Intervention: BATT 10 mg
Number of subjects: 24
Study 12475391 — intervention group
Group type: EXPERIMENTAL
Intervention: BATT 20 mg
Number of subjects: 24
Study 12475391 — intervention group
Group type: EXPERIMENTAL
Intervention: BATT 30 mg
Number of subjects: 24
Study 9552036 — intervention group
Group type: EXPERIMENTAL
Intervention: ECycloF (infusional fluorouracil, epirubicin, and cyclophosphamide)
Number of subjects: 96
Study 9552036 — intervention group
Group type: COMPARATOR
Intervention: ECisF (infusional fluorouracil, epirubicin, and cisplatin)
Number of subjects: 96
Study 8160616 — intervention group
Group type: EXPERIMENTAL
Intervention: Decaffeinated coffee
Number of subjects: 186
Study 8160616 — intervention group
Group type: COMPARATOR
Intervention: Caffeinated coffee (control)
Number of subjects: 186
Study 3341564 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of EMLA cream for 15 minutes
Number of subjects: 0
Study 3341564 — intervention group
Group type: COMPARATOR
Intervention: Local injection of lidocaine
Number of subjects: 0
Study 3341564 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of EMLA cream for 80 minutes
Number of subjects: 0
Study 3341564 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of EMLA cream for 100 minutes
Number of subjects: 0
Study 3341564 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of EMLA cream for 120 minutes
Number of subjects: 0
Study 30005019 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% daily dosing of TDF/FTC for 12 weeks
Number of subjects: 47
Study 30005019 — intervention group
Group type: EXPERIMENTAL
Intervention: 67% daily dosing of TDF/FTC for 12 weeks
Number of subjects: 47
Study 30005019 — intervention group
Group type: EXPERIMENTAL
Intervention: 33% daily dosing of TDF/FTC for 12 weeks
Number of subjects: 47
Study 28399933 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal administration of ketamine (4.0 mg/kg, maximum 100 mg) and midazolam (0.2 mg/kg, maximum 5.0 mg)
Number of subjects: 84
Study 28399933 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of ketamine (4.0 mg/kg, maximum 100 mg) and midazolam (0.5 mg/kg, maximum 20 mg)
Number of subjects: 84
Study 28399933 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of midazolam (1.0 mg/kg, maximum 20 mg)
Number of subjects: 84
Study 26018529 — intervention group
Group type: EXPERIMENTAL
Intervention: CogState Schizophrenia Battery (SB)
Number of subjects: 143
Study 26018529 — intervention group
Group type: EXPERIMENTAL
Intervention: MATRICS Consensus Cognitive Battery (MCCB)
Number of subjects: 143
Study 26018529 — intervention group
Group type: EXPERIMENTAL
Intervention: MATRICS Consensus Cognitive Battery (MCCB) and CogState Schizophrenia Battery (SB)
Number of subjects: 143
Study 23982225 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) focusing on behavioral exposure
Number of subjects: 49
Study 21939883 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacteriostatic normal saline (BNS)
Number of subjects: 56
Study 21939883 — intervention group
Group type: COMPARATOR
Intervention: 1% buffered lidocaine (Lido)
Number of subjects: 56
Study 18310164 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental intervention (breastfeeding promotion intervention)
Number of subjects: 17046
Study 17227520 — intervention group
Group type: EXPERIMENTAL
Intervention: F-actin ELISA
Number of subjects: 170
Study 17227520 — intervention group
Group type: COMPARATOR
Intervention: SMA-IFT
Number of subjects: 170
Study 14624699 — intervention group
Group type: EXPERIMENTAL
Intervention: 12/15/18 diet group (1200 kcal/day for 12 weeks, 1500 kcal/day for 16 weeks, 1800 kcal/day for 12 weeks)
Number of subjects: 90
Study 14624699 — intervention group
Group type: COMPARATOR
Intervention: 15/18 diet group (1500 kcal/day for 28 weeks, 1800 kcal/day for 12 weeks)
Number of subjects: 90
Study 10934672 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg
Number of subjects: 14
Study 10934672 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin 40 mg + Irbesartan 300 mg
Number of subjects: 14
Study 10934672 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 14
Study 8925993 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers with EPH gestosis
Number of subjects: 61